Every Form 4 that Ingevity Corporation (NGVT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NGVT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NGVT filings page.
Ingevity Corp director Francis David Segal received 335 vested deferred stock units (DSUs) on October 1, 2026, in lieu of quarterly director fees, following his election to receive DSUs instead of those fees. The transaction lists $71.09 per share, and Segal’s reported direct position following the transaction was 8,947 shares.
Ingevity Corp director J. Kevin Willis received 405 vested deferred stock units on October 1, 2026, reported at $71.09 per share. The units were granted in lieu of quarterly director fees and will settle into an equal number of common shares upon termination of board service. His reported post-transaction position was 11,883 shares.
Ingevity Corp (NGVT) reported that President & CEO David H. Li sold company common stock in three open-market transactions under a Rule 10b5-1 trading plan. On August 14, 2026 he sold 5,000 shares at a weighted average price of $75.73, with individual trades between $74.82 and $76.53. On August 17, 2026 he sold another 5,000 shares at a weighted average price of $75.83, with prices between $75.50 and $76.25. On August 18, 2026 he sold 92 shares at a weighted average price of $74.71, with trades between $74.39 and $74.96. In total, the filing reports sales of 10,092 shares of NGVT common stock held directly by Li.
Ingevity Corp President & CEO David H. Li reported open-market sales of company common stock under a Rule 10b5-1 trading plan. He sold 5,000 shares on August 12, 2026 at a weighted average price of $76.62 and 5,000 shares on August 13, 2026 at a weighted average price of $75.73, each executed through multiple trades within disclosed price ranges.
Ingevity Corp officer Phillip John Platt, SVP and Chief Financial Officer, reported a Form 4 transaction involving company common stock. On 2026-08-10, 1,698 shares were withheld by the company at $77.04 per share to satisfy tax withholding obligations related to 2024 restricted stock units that vested. Following this tax-withholding disposition, Platt’s directly held common stock position is 26,641 shares.
Ingevity Corp executive Ryan C. Fisher, SVP, General Counsel & Secretary, reported selling a total of 2,709 shares of common stock on August 3, 2026. The sales occurred in two non-derivative transactions classified as sales in open market or private transactions at $73.7600 and $73.6700 per share. The Rule 10b5-1 trading plan checkbox was not checked for these trades.
Ingevity Corp reports that SVP and Chief Financial Officer Phillip John Platt had 3,294 shares of common stock withheld by the company on July 24, 2026 at $73.26 per share to satisfy tax withholding obligations on vested restricted stock units, leaving 28,339 shares held directly.
Ingevity Corp senior vice president and general counsel Ryan C. Fisher reported a routine tax-related share disposition. The company withheld 168 shares of common stock at $73.86 per share to satisfy tax obligations on 2024 RSUs that vested.
After this withholding, Fisher directly holds 18,431 shares of Ingevity common stock, indicating the transaction is small relative to his overall position.
Ingevity Corp director Kevin J. Willis reported an award of 397 shares of common stock-equivalent deferred stock units, valued using a reference price of $72.58 per share. Following this grant, his directly owned and deferred stock unit-equivalent holdings total 11,478 shares.
These units represent vested deferred stock units received in lieu of quarterly director fees. Under Ingevity’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan, the units will convert into an equal number of common shares when his board service ends.
Ingevity Corp director Francis David Segal reported an acquisition of 328 shares of Common Stock, recorded as a grant or award valued at $72.58 per share. Following this award, his direct holdings increased to 8,612 shares.
According to the footnote, the 328 vested deferred stock units were granted under Segal’s election to receive DSUs instead of quarterly director fees. These DSUs will convert into an equal number of Ingevity common shares when his board service ends, under the company’s deferred compensation and 2025 omnibus incentive plans.
Cotterman Ryan Joseph reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp reported that VP and Chief Accounting Officer Ryan Joseph Cotterman received an equity grant of 2,063 shares of common stock as a compensation award. The grant represents restricted stock units under the Ingevity Corporation 2025 Omnibus Incentive Plan, issued at no cash cost to him.
These restricted stock units will vest in three equal installments on June 22, 2027, 2028, and 2029, tying part of his compensation to future service and company performance. Following this award, Cotterman directly holds 2,063 shares linked to this grant.
Ingevity Corp senior vice president and Chief HR Officer Terrance M. Dyer reported open-market sales of company common stock. On May 28, 2026, he sold a total of 496 shares of Ingevity common stock in three transactions at prices between $68.45 and $68.57 per share.
PLATT PHILLIP JOHN reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp senior vice president of finance and chief accounting officer Phillip John Platt received a grant of 1,262 restricted stock units (RSUs) of common stock on May 1, 2026. This was awarded under the Ingevity Corporation 2025 Omnibus Incentive Plan and is compensation rather than a market purchase.
The RSUs will vest in three equal installments on May 1, 2027, 2028, and 2029, meaning the shares are earned over time if service conditions are met. After this award, Platt directly holds 31,633 shares of Ingevity common stock, which includes 422 shares purchased through the company’s Employee Stock Purchase Plan for the period from January 1, 2026 to March 31, 2026 at a price equal to 85% of the December 31, 2025 closing price.
Ingevity Corp director Luis M. Fernandez-Moreno received an equity award of 1,904 shares of common stock on April 30, 2026. The award was granted as restricted stock units under Ingevity Corporation's 2025 Omnibus Incentive Plan and carries no cash exercise price.
The restricted stock units will vest in full on April 30, 2027, meaning the director must remain eligible through that date to receive the shares outright. Following this compensation-related grant, Fernandez-Moreno directly holds 37,882 shares of Ingevity common stock as reported in this filing.
Gulyas Diane H. reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp director Diane H. Gulyas received 1,904 shares of common stock as a grant of restricted stock units. The award was granted at a price of $0.00 per share under Ingevity Corporation's 2025 Omnibus Incentive Plan and will vest in full on April 30, 2027.
Following this grant, she holds 14,788 shares of Ingevity common stock directly. Separately, 3,747 shares are held indirectly through the Diane H. Gulyas Trust, where she serves as trustee and her spouse is the beneficiary.
Ingevity Corp director Bruce D. Hoechner received a grant of 1,904 deferred stock units (DSUs) of Common Stock as equity compensation. The award was made in lieu of the annual non-employee director restricted stock unit grant and carries no cash exercise price.
The DSUs will vest on April 30, 2027 and will convert into an equal number of Ingevity Common Stock shares when his board service ends, under the company’s Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. Following this grant, Hoechner directly holds 10,732 shares.
Lynch Frederick J reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp director Frederick J. Lynch reported a compensation-related equity award. He received 1,904 restricted stock units of Ingevity common stock at no purchase price under the company’s 2025 Omnibus Incentive Plan. These units will vest in full on April 30, 2027, bringing his direct holdings to 28,263 shares after the grant.
NARWOLD KAREN G reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp director receives equity award through a grant of 1,904 shares of common stock to Karen G. Narwold. The grant is reported at a price of $0.00 per share as a compensation-related award, not an open-market purchase, and increases her direct holdings to 18,900 shares.
The award represents restricted stock units granted under Ingevity Corporation's 2025 Omnibus Incentive Plan and is scheduled to vest in full on April 30, 2027. This filing records a routine equity-based compensation grant rather than a discretionary stock trade.
Segal Francis David reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp director Francis David Segal reported receiving an equity award under the company’s 2025 Omnibus Incentive Plan. He was granted 1,904 shares of Common Stock at no cost, structured as restricted stock units that will vest in full on April 30, 2027. Following this grant, he directly holds 8,284 shares of Ingevity common stock.
Ingevity Corp director Kevin J. Willis received an equity award of 1,904 deferred stock units. The grant reflects his election to take deferred stock units instead of the usual annual restricted stock unit grant for non-employee directors.
The deferred stock units will vest on April 30, 2027 and will convert into an equal number of Ingevity common shares when his board service ends, under the company’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. After this award, he holds 11,081 shares directly.
Ingevity director Benjamin G. Wright received an equity grant in the form of deferred stock units. He was granted 1,904 deferred stock units in lieu of the annual non-employee director restricted stock unit grant, at no cash cost per unit. These units will vest on April 30, 2027 and will convert into the same number of Ingevity common shares after his board service ends, under the company’s Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. Following this grant, he directly holds 11,948 shares.
Ingevity Corp President & CEO David H. Li reported routine tax-related share dispositions rather than open-market sales. On April 7, 2026, a total of 16,676 shares of Common Stock were withheld at $70.57 per share to cover tax obligations. After these transactions, Li directly held 140,636 shares of Ingevity common stock. A footnote notes that this total includes 422 ESPP shares purchased for the January 1 to March 31, 2026 period at 85% of the December 31, 2025 closing price.
Ingevity Corp director Francis David Segal received a grant of 329 vested deferred stock units at $72.28 per unit. These units were issued in lieu of quarterly director fees and increase his directly owned common stock-related position to 6,380 shares.
The deferred stock units will convert into an equal number of Ingevity common shares when his board service ends, under the company’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.
Ingevity Corp director J. Kevin Willis reported an equity award of 398 shares of Common Stock on Form 4. The award reflects vested deferred stock units elected in lieu of quarterly director fees at an implied price of $72.28 per share. Following this grant, Willis directly holds 9,177 shares. These deferred stock units will convert into an equal number of Ingevity common shares when his board service ends under the company’s Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.
Ingevity Corp senior executive handles RSU tax obligations through share withholding. SVP, General Counsel & Secretary Ryan C. Fisher had 308 shares of common stock withheld by the company at a price of $71.78 per share to satisfy tax liabilities from 2024 RSUs that vested. After this tax-withholding disposition, he directly holds 18,194 common shares.
Ingevity Corp senior vice president of operations Clarence Reid Clontz Jr. reported equity compensation changes. He acquired 2,343 shares of common stock on a grant or award basis at $0.00 per share, tied to restricted stock units under the Ingevity Corporation 2025 Omnibus Incentive Plan that will vest in three equal installments on February 27, 2027, 2028, and 2029. He also had several small tax-withholding dispositions on March 2, 2026, where 143, 264, 49, and 270 shares of common stock were withheld by the company at $71.64 per share to satisfy tax obligations related to 2023, 2024, and 2025 RSUs that vested. Following these transactions, his directly owned common stock holdings were reported in the 9,000–9,700 share range after each step.
Ingevity Corp senior vice president of finance and chief accounting officer Phillip John Platt reported a mix of equity grants and tax-related share dispositions. On February 27, 2026, he acquired 2,108 restricted stock units under the 2025 Omnibus Incentive Plan, vesting in three equal installments on February 27, 2027, 2028, and 2029. On March 2, 2026, the company withheld a total of 1,070 common shares at $71.64 per share to cover tax obligations tied to vested RSUs from 2023, 2024, and 2025, reducing his directly owned common stock to 29,949 shares.
Ingevity Corp executive Ryan C. Fisher, SVP, General Counsel & Secretary, reported equity compensation activity and related tax withholding. On February 27, 2026, he acquired 4,442 shares of common stock at $0.00 per share as a grant of restricted stock units under the Ingevity Corporation 2025 Omnibus Incentive Plan, scheduled to vest in three equal installments on February 27, 2027, February 27, 2028, and February 27, 2029. On March 2, 2026, a total of 1,333 shares of common stock were disposed of in four transactions coded as tax-withholding dispositions at $71.64 per share, with footnotes stating the shares were withheld by the company to satisfy tax withholding obligations related to vested RSUs from 2023, 2024, and 2025. Following these transactions, Fisher directly owned 18,502 shares of Ingevity common stock.
Ingevity Corp senior executive Richard Allen White Jr. reported several tax-related share dispositions of common stock. On March 2, 2026, shares were withheld by the company at $71.64 per share to cover tax withholding obligations tied to restricted stock units that vested in 2023, 2024, and 2025. These were tax-withholding transactions, not open market sales, and White continues to hold a meaningful direct ownership stake after the withholdings.
Ingevity Corp executive vice president and chief financial officer Mary Dean Hall reported tax-related share dispositions on common stock. On March 2, 2026, she surrendered a total of 4,148 shares at $71.64 per share to satisfy withholding taxes on vesting RSU awards from 2023, 2024, and 2025. These are coded as “F” transactions, meaning shares were withheld by the company to cover tax obligations rather than sold in open-market trades. After these transactions, she directly holds 37,427 shares of Ingevity common stock.
Ingevity Corp senior vice president and chief HR officer Terrance M. Dyer reported equity compensation and a related tax withholding transaction. He received a grant of 3,621 shares of common stock at $0.00 per share, tied to restricted stock units that vest in three equal installments on February 27, 2027, 2028, and 2029. To cover tax withholding on 2025 RSUs that vested, 550 shares were disposed at $71.64 per share. After these transactions, he directly holds 7,698 common shares.
Ingevity Corp senior executive receives equity award. SVP and President, APT, Michael N. Shukov acquired 1,389 shares of Ingevity common stock on a grant basis, with no cash paid per share. The award is in the form of restricted stock units under the Ingevity Corporation 2025 Omnibus Incentive Plan.
The units will vest in three equal installments on February 27, 2027, February 27, 2028, and February 27, 2029, aligning the executive’s compensation with longer-term company performance through time-based vesting.
Castillo Ruth reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp senior executive Ruth Castillo, SVP and President of Performance Materials, reported receiving a grant of 3,688 shares of common stock as a stock award. These restricted stock units were granted at no cash cost and will vest in three equal installments on February 27, 2027, 2028, and 2029.
Li David H reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp President & CEO David H. Li reported an equity award of 38,179 shares of common stock. The filing labels this as a grant or award, with a price of $0.0000 per share, indicating it is a stock-based compensation grant rather than an open-market purchase.
According to the footnotes, the award consists of restricted stock units granted under the Ingevity Corporation 2025 Omnibus Incentive Plan and scheduled to vest in three equal installments on February 27, 2027, 2028, and 2029. After this grant, Li’s directly held common stock position is reported as 156,890 shares, which includes earlier purchases of 364 and 162 shares through the company’s employee stock purchase plan.
Ingevity Corp EVP and CFO Mary Dean Hall reported equity award activity involving company common stock. On February 26, 2026, she acquired 1,780 shares through the settlement of performance-based restricted stock units after the Talent and Compensation Committee certified that performance goals were met. On the same date, 873 shares were withheld by the company to cover tax obligations related to these vested awards. Following these transactions, she directly owned 41,775 shares of Ingevity common stock.
Ingevity Corp senior executive Richard Allen White Jr., SVP and President of Performance Chemicals, reported stock-based compensation awards of common stock. On February 26, 2026, he acquired 1,204 shares at $0 per share and 430 shares at $70.52 per share as grant or award transactions. Footnotes explain that performance-based restricted stock units were certified and settled in common shares rather than cash.
Ingevity Corp senior vice president Phillip John Platt reported equity compensation activity involving company common stock. On February 26, 2026, he acquired 247 shares at no cost through a grant tied to performance-based restricted stock units that were settled in shares. On the same date, 108 shares at $70.52 per share were withheld by the company to cover tax obligations related to these vested performance share units. Following these transactions, his directly held common stock balance reported in the filing was 28,911 shares.
Ingevity Corp senior vice president and general counsel Ryan C. Fisher reported equity compensation activity involving company common stock. On February 26, 2026, he acquired 192 shares at a stated price of $0.00 per share from the vesting and settlement of performance-based restricted stock units. On the same date, the company withheld 94 shares at a price of $70.52 per share to cover tax obligations related to this vesting. After these transactions, Fisher directly owned 15,393 shares of Ingevity common stock.
Ingevity Corp senior vice president Clarence Reid Clontz Jr. reported performance-based equity compensation activity involving company common stock. On February 26, 2026, he acquired 187 shares of common stock at $0.00 per share as a grant related to performance-based restricted stock awards (PSUs) whose performance goals were certified and settled in stock.
On the same date, 69 shares were disposed of at $70.52 per share through shares withheld by the company to cover tax withholding obligations tied to the PSU vesting, rather than an open-market sale. After these transactions, he directly held 7,363 common shares, which includes 216 shares previously purchased through the company’s employee stock purchase plan.
Ingevity Corp director reports routine stock-based compensation. Director Francis David Segal acquired 396 shares of Ingevity common stock on 01/02/2026 at a price of $60.09 per share. Following this transaction, he beneficially owns 6,051 shares of Ingevity common stock in direct ownership.
The reported shares represent vested deferred stock units that were granted under Ingevity’s director compensation programs, where the director elected to receive deferred stock units instead of cash quarterly director fees. These deferred stock units will convert into an equal number of Ingevity common shares when his service on the board ends, in line with the company’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.
Ingevity Corp director reports stock-based compensation transaction
A director of Ingevity Corp reported acquiring 479 shares of the company’s common stock on 01/02/2026 at a price of $60.09 per share. These shares represent vested deferred stock units the director elected to receive instead of quarterly cash director fees, under Ingevity’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. After this transaction, the director beneficially owns 8,779 shares of Ingevity common stock in direct ownership. The deferred stock units will convert into an equal number of common shares when the director’s board service ends.